Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Short Interest Update

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 8,250,000 shares, an increase of 5.4% from the January 15th total of 7,830,000 shares. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 5.5 days. Currently, 22.6% of the shares of the company are short sold.

Ginkgo Bioworks Trading Up 8.7 %

DNA opened at $14.73 on Tuesday. Ginkgo Bioworks has a 1-year low of $5.26 and a 1-year high of $64.40. The firm has a fifty day simple moving average of $11.34.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new position in Ginkgo Bioworks during the 4th quarter worth $29,000. KBC Group NV bought a new position in Ginkgo Bioworks during the 4th quarter worth $31,000. KLP Kapitalforvaltning AS bought a new position in Ginkgo Bioworks during the 4th quarter worth $46,000. Mercer Global Advisors Inc. ADV bought a new position in Ginkgo Bioworks during the 4th quarter worth $116,000. Finally, Palumbo Wealth Management LLC bought a new position in Ginkgo Bioworks during the 4th quarter worth $144,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.